{"id":10430,"date":"2025-05-07T16:42:38","date_gmt":"2025-05-07T20:42:38","guid":{"rendered":"https:\/\/thetimesfinancial.com\/?p=10430"},"modified":"2025-05-07T16:42:40","modified_gmt":"2025-05-07T20:42:40","slug":"pharmaceutical-imports-surge-ahead-of-potential-u-s-tariffs","status":"publish","type":"post","link":"https:\/\/thetimesfinancial.com\/?p=10430","title":{"rendered":"Pharmaceutical Imports Surge Ahead of Potential U.S. Tariffs"},"content":{"rendered":"\n<p>Pharmaceutical imports to the U.S. skyrocketed in March, as drugmakers rushed to stock up ahead of potential tariffs on their products. Historically exempt from such tariffs, pharmaceuticals saw an unexpected surge, totaling over <strong>$50 billion<\/strong> for the month. This represents about <strong>20%<\/strong> of all pharmaceutical imports for 2024, according to a report released by the U.S. Commerce Department on Tuesday.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Spike in Imports from Ireland<\/h2>\n\n\n\n<p>The biggest contributor to this increase came from <strong>Ireland<\/strong>, the largest exporter of drugs to the U.S. Imports from Ireland surged, helping the country surpass China in trade surplus with the U.S. for the first time in March. Imports from Ireland jumped by about <strong>$15.5 billion<\/strong> from February, with pharmaceuticals making up the majority of that increase.<\/p>\n\n\n\n<p>\u201cWhile it was expected that consumer goods would account for much of the rise in imports, pharmaceutical products accounted for <strong>$20 billion<\/strong> of the increase, nearly all imported from Ireland,\u201d said <strong>Matthew Martin<\/strong>, senior economist at Oxford Economics.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Trump\u2019s Threat of Tariffs on Pharmaceuticals<\/h2>\n\n\n\n<p><strong>President Donald Trump<\/strong> has threatened to impose tariffs on pharmaceuticals as part of his broader trade policy, aiming to boost domestic drug production. Last month, his administration launched a probe into pharmaceutical imports, potentially classifying foreign reliance on drug production as a national security threat.<\/p>\n\n\n\n<p>Trump has promised to announce a decision regarding these tariffs within the next two weeks, in addition to signing an executive order to reduce the regulatory burden on U.S. drug manufacturing.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Drugmakers Stockpiling Ahead of Tariffs<\/h2>\n\n\n\n<p>In response to the tariff threat, drugmakers have been taking proactive steps to mitigate potential disruption. Some have opted to send more medications by air to the U.S. to ensure timely delivery. <strong>Pfizer<\/strong> CEO <strong>Albert Bourla<\/strong> mentioned in a recent investor call that the company had increased its inventory each month to ensure it is well-prepared for the tariffs.<\/p>\n\n\n\n<p>Similarly, <strong>Merck<\/strong> has moved enough inventory of its blockbuster cancer drug <strong>Keytruda<\/strong> \u2014 much of which is produced in Ireland \u2014 to ensure steady supply through the end of the year.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Impact on Global Trade Partners<\/h2>\n\n\n\n<p>Beyond Ireland, other countries at risk from these potential tariffs include <strong>Singapore<\/strong> and <strong>Switzerland<\/strong>, both major exporters of pharmaceuticals to the U.S. According to Oxford\u2019s Martin, these nations could face significant impacts should U.S. tariffs be imposed on drug imports.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pharmaceutical imports to the U.S. skyrocketed in March, as drugmakers rushed to stock up ahead of potential tariffs on their products. Historically exempt from such tariffs, pharmaceuticals saw an unexpected surge, totaling over $50 billion for the month. This represents about 20% of all pharmaceutical imports for 2024, according to a report released by the [&hellip;]<\/p>\n","protected":false},"author":10772,"featured_media":10431,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[19],"tags":[1493,1495,1496,1497,1490,1491,1494,1492,1498,723,1085,1078],"class_list":{"0":"post-10430","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-business","8":"tag-drugmakers","9":"tag-inventory","10":"tag-ireland","11":"tag-keytruda","12":"tag-merck","13":"tag-national-security","14":"tag-pfizer","15":"tag-pharmaceutical-imports","16":"tag-tariffs-on-medicines","17":"tag-trade-surplus","18":"tag-trump-administration","19":"tag-u-s-tariffs"},"_links":{"self":[{"href":"https:\/\/thetimesfinancial.com\/index.php?rest_route=\/wp\/v2\/posts\/10430","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thetimesfinancial.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thetimesfinancial.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thetimesfinancial.com\/index.php?rest_route=\/wp\/v2\/users\/10772"}],"replies":[{"embeddable":true,"href":"https:\/\/thetimesfinancial.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10430"}],"version-history":[{"count":1,"href":"https:\/\/thetimesfinancial.com\/index.php?rest_route=\/wp\/v2\/posts\/10430\/revisions"}],"predecessor-version":[{"id":10432,"href":"https:\/\/thetimesfinancial.com\/index.php?rest_route=\/wp\/v2\/posts\/10430\/revisions\/10432"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/thetimesfinancial.com\/index.php?rest_route=\/wp\/v2\/media\/10431"}],"wp:attachment":[{"href":"https:\/\/thetimesfinancial.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10430"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thetimesfinancial.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10430"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thetimesfinancial.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10430"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}